GlucoTrack, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from GlucoTrack, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 6.5 times its market value (net cash). Higher than almost all Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 35,157% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 97% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-4.8×Operating cash was negative last year, while some debt falls due within a year.
Higher than 59% of Healthcare companies in United States.
Cash Cushion Ratio
6.5× cashCash, after subtracting all debt, is 6.5 times its market value (net cash).
Higher than almost all Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
GlucoTrack, Inc. made a loss over the last year. GlucoTrack, Inc. owes $2.16 for every $1 it owns. GlucoTrack, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossGlucoTrack, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-0.35GlucoTrack, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$1 MThe total market value of all of GlucoTrack, Inc.'s shares at today's price (share price × number of shares), smaller than almost all Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
NegativeGlucoTrack, Inc.'s net worth is negative ($2 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-620.6%GlucoTrack, Inc. lost 620.6% of its shareholders' money over the last year, lower than 95% of Healthcare companies in United States.
Owes vs Owns
2.16×GlucoTrack, Inc. owes $2.16 for every $1 it owns, so it owes more than it owns, higher than 96% of Healthcare companies in United States.
Dividend yield
NoneGlucoTrack, Inc. does not currently pay a dividend.
Profit growth
LossGlucoTrack, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashGlucoTrack, Inc. held $4 M more cash than debt (net cash) at Dec 2025.
Questions
What is GlucoTrack, Inc.'s return on equity?
GlucoTrack, Inc. lost 620.6% of its shareholders' money over the last year, lower than 95% of Healthcare companies in United States.
How much does GlucoTrack, Inc. owe compared with what it owns?
GlucoTrack, Inc. owes $2.16 for every $1 it owns, so it owes more than it owns, higher than 96% of Healthcare companies in United States.
Does GlucoTrack, Inc. pay a dividend?
No. GlucoTrack, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.